Intervacc is trading 16.38% down at €0.07, with the immediate catalyst unclear.
- The January–June 2026 interim report, released August 20, 2026, was described as having “few surprises,” without a specific negative earnings catalyst identified.
- Biotech stocks weakened 2.47% as investors took profits after Moderna-driven gains and reacted to financing pressure elsewhere in biotechnology, but the move does not fully explain Intervacc’s decline.